FRAILTYDIABETESCD26 antigenThe article focuses on comparing the cardiovascular effectiveness and safety of Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors... G Maltese,AJ Sinclair - 《Diabetes Care》 被引量: 0发表: 2024年 Diabetes, hemoglobin A1c, and cognitive performance in older adults: ...
Empagliflozin, a selective sodium/glucose cotransporter 2 (SGLT2) inhibitor, is approved for use in type 2 diabetes mellitus (T2DM) patients as a hypoglycaemic agent. Recently, it has been recognized to be beneficial for several other conditions including NAFLD. A number of small-scale clinical ...